Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in App
Aging
Alzheimer Disease
/ genetics
Amyloid beta-Peptides
Animals
Brain
/ metabolism
Cognitive Dysfunction
Disease Models, Animal
Drug Discovery
Female
Gene Expression Regulation, Neoplastic
Gene Knock-In Techniques
Humans
Mice
Mice, Inbred C57BL
Mice, Transgenic
Plaque, Amyloid
/ metabolism
Proteomics
/ methods
Transcriptome
Alzheimer’s disease
Data-driven drug discovery
In vivo models
Proteomics
Transcriptomics
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
16
04
2021
accepted:
29
09
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
22
2
2022
Statut:
epublish
Résumé
In spite of many years of research, our understanding of the molecular bases of Alzheimer's disease (AD) is still incomplete, and the medical treatments available mainly target the disease symptoms and are hardly effective. Indeed, the modulation of a single target (e.g., β-secretase) has proven to be insufficient to significantly alter the physiopathology of the disease, and we should therefore move from gene-centric to systemic therapeutic strategies, where AD-related changes are modulated globally. Here we present the complete characterization of three murine models of AD at different stages of the disease (i.e., onset, progression and advanced). We combined the cognitive assessment of these mice with histological analyses and full transcriptional and protein quantification profiling of the hippocampus. Additionally, we derived specific Aβ-related molecular AD signatures and looked for drugs able to globally revert them. We found that AD models show accelerated aging and that factors specifically associated with Aβ pathology are involved. We discovered a few proteins whose abundance increases with AD progression, while the corresponding transcript levels remain stable, and showed that at least two of them (i.e., lfit3 and Syt11) co-localize with Aβ plaques in the brain. Finally, we found two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice while reducing Aβ plaques in the hippocampus and partially restoring the physiological levels of AD signature genes to wild-type levels. The characterization of three AD mouse models at different disease stages provides an unprecedented view of AD pathology and how this differs from physiological aging. Moreover, our computational strategy to chemically revert AD signatures has shown that NSAID and anti-hypertensive drugs may still have an opportunity as anti-AD agents, challenging previous reports.
Sections du résumé
BACKGROUND
In spite of many years of research, our understanding of the molecular bases of Alzheimer's disease (AD) is still incomplete, and the medical treatments available mainly target the disease symptoms and are hardly effective. Indeed, the modulation of a single target (e.g., β-secretase) has proven to be insufficient to significantly alter the physiopathology of the disease, and we should therefore move from gene-centric to systemic therapeutic strategies, where AD-related changes are modulated globally.
METHODS
Here we present the complete characterization of three murine models of AD at different stages of the disease (i.e., onset, progression and advanced). We combined the cognitive assessment of these mice with histological analyses and full transcriptional and protein quantification profiling of the hippocampus. Additionally, we derived specific Aβ-related molecular AD signatures and looked for drugs able to globally revert them.
RESULTS
We found that AD models show accelerated aging and that factors specifically associated with Aβ pathology are involved. We discovered a few proteins whose abundance increases with AD progression, while the corresponding transcript levels remain stable, and showed that at least two of them (i.e., lfit3 and Syt11) co-localize with Aβ plaques in the brain. Finally, we found two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice while reducing Aβ plaques in the hippocampus and partially restoring the physiological levels of AD signature genes to wild-type levels.
CONCLUSIONS
The characterization of three AD mouse models at different disease stages provides an unprecedented view of AD pathology and how this differs from physiological aging. Moreover, our computational strategy to chemically revert AD signatures has shown that NSAID and anti-hypertensive drugs may still have an opportunity as anti-AD agents, challenging previous reports.
Identifiants
pubmed: 34702310
doi: 10.1186/s13073-021-00983-y
pii: 10.1186/s13073-021-00983-y
pmc: PMC8547095
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
168Informations de copyright
© 2021. The Author(s).
Références
Neuron. 2020 Mar 18;105(6):975-991.e7
pubmed: 31926610
Science. 2006 Nov 3;314(5800):777-81
pubmed: 17082447
Ann Neurol. 2014 Aug;76(2):185-205
pubmed: 24853080
Cell Rep. 2017 Oct 10;21(2):366-380
pubmed: 29020624
Alzheimers Res Ther. 2020 Mar 2;12(1):21
pubmed: 32122400
Genome Biol. 2015 Feb 22;16:41
pubmed: 25853883
Cell Rep. 2019 Apr 9;27(2):467-480.e6
pubmed: 30970250
Neuropharmacology. 2007 Feb;52(2):291-6
pubmed: 17074372
CNS Drugs. 2017 Dec;31(12):1057-1082
pubmed: 29260466
Nat Immunol. 2015 Mar;16(3):229-36
pubmed: 25689443
Methods Mol Biol. 2007;401:365-81
pubmed: 18368375
Nature. 2001 Nov 8;414(6860):212-6
pubmed: 11700559
Lancet Neurol. 2010 Jul;9(7):702-16
pubmed: 20610346
Exp Mol Med. 2019 Nov 15;51(11):1-17
pubmed: 31727875
Neurology. 2008 May 6;70(19):1672-7
pubmed: 18458226
Nat Rev Drug Discov. 2010 May;9(5):387-98
pubmed: 20431570
Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12711-6
pubmed: 26420877
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Neurobiol Aging. 2014 Jul;35(7):1596-604
pubmed: 24524963
Mol Neurodegener. 2018 Jan 16;13(1):2
pubmed: 29338754
Cell Rep. 2020 Feb 11;30(6):2040-2054.e5
pubmed: 32049030
Lancet. 2011 Feb 19;377(9766):641-9
pubmed: 21292315
Nat Protoc. 2013 Dec;8(12):2531-7
pubmed: 24263092
Genome Biol. 2006;7 Suppl 1:S4.1-9
pubmed: 16925838
J Proteomics. 2014 Oct 14;110:45-58
pubmed: 25108202
Lancet Neurol. 2005 Aug;4(8):487-99
pubmed: 16033691
Cell Syst. 2015 Sep 23;1(3):224-37
pubmed: 27135913
Nat Commun. 2018 Jan 8;9(1):81
pubmed: 29311685
Ann Appl Stat. 2014 Mar;8(1):309-330
pubmed: 24795787
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Curr Top Behav Neurosci. 2013;15:313-40
pubmed: 23670818
Eur J Pharmacol. 2010 Feb 10;627(1-3):223-8
pubmed: 19879866
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
N Engl J Med. 2016 Dec 29;375(26):2519-29
pubmed: 27959716
Genome Biol. 2014;15(12):550
pubmed: 25516281
Elife. 2015 Dec 01;4:e08527
pubmed: 26422514
Cell Rep. 2015 Feb 3;10(4):633-44
pubmed: 25620700
Nat Neurosci. 2018 Jun;21(6):811-819
pubmed: 29802388
Cold Spring Harb Perspect Med. 2012 Oct 01;2(10):
pubmed: 23028126
Cell. 1988 Feb 26;52(4):487-501
pubmed: 3257719
Nat Med. 2011 Sep 07;17(9):1060-5
pubmed: 21900936
Cell Mol Life Sci. 2017 Apr;74(7):1335-1345
pubmed: 27853832
Lancet Neurol. 2020 Mar;19(3):247-254
pubmed: 31999942
Sci Rep. 2015 Oct 29;5:15862
pubmed: 26511387
Brain Res. 2010 Dec 17;1366:233-45
pubmed: 20934413
Nat Immunol. 2018 Oct;19(10):1048-1058
pubmed: 30250185
J Alzheimers Dis Rep. 2018 Feb 16;2(1):27-39
pubmed: 30480246
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Clin Drug Investig. 2019 May;39(5):463-468
pubmed: 30868473
Nat Neurosci. 2019 Oct;22(10):1696-1708
pubmed: 31551601
Chem Sci. 2017 Oct 31;9(2):513-530
pubmed: 29629118
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
N Engl J Med. 2001 Nov 22;345(21):1515-21
pubmed: 11794217
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):
pubmed: 23002015
Biomed Res Int. 2020 May 24;2020:8456596
pubmed: 32596386
Sci Adv. 2021 Jan 6;7(2):
pubmed: 33523961
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
EMBO J. 2017 Sep 1;36(17):2473-2487
pubmed: 28768718
Immunity. 2017 Jun 20;46(6):957-967
pubmed: 28636962
Biom J. 2008 Jun;50(3):346-63
pubmed: 18481363
Sci Rep. 2017 Nov 15;7(1):15637
pubmed: 29142239
Endocrinology. 2010 Dec;151(12):5841-50
pubmed: 20881240
Cell Rep. 2017 Nov 28;21(9):2614-2627
pubmed: 29186695
Genome Biol. 2003;4(9):117
pubmed: 12952525
Front Aging Neurosci. 2018 Apr 25;10:114
pubmed: 29922147
Mol Biosyst. 2009 Dec;5(12):1512-26
pubmed: 20023718
Neurobiol Aging. 2013 Apr;34(4):1105-15
pubmed: 23063647
N Engl J Med. 2013 Jan 10;368(2):107-16
pubmed: 23150908
Alzheimers Res Ther. 2018 Jan 29;10(1):9
pubmed: 29378650
Sci Rep. 2017 Dec 19;7(1):17762
pubmed: 29259249
Nucleic Acids Res. 2021 Jan 8;49(D1):D1302-D1310
pubmed: 33196847
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Commun. 2016 Aug 11;7:12504
pubmed: 27509875
J Biol Chem. 1995 Apr 21;270(16):9564-70
pubmed: 7721886
Acta Neuropathol. 2017 Jun;133(6):933-954
pubmed: 28258398
Cell. 2015 May 21;161(5):999-1011
pubmed: 26000480
Neuropharmacology. 2014 Jun;81:311-7
pubmed: 24631967
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cell. 2014 Nov 6;159(4):721-6
pubmed: 25417150
Mol Cell Proteomics. 2004 Dec;3(12):1154-69
pubmed: 15385600
Genes Dev. 2019 Mar 1;33(5-6):365-376
pubmed: 30808661
Brain. 2016 Jul;139(Pt 7):2063-81
pubmed: 27190010
Lancet Neurol. 2015 Sep;14(9):926-944
pubmed: 26213339
Nat Neurosci. 2014 May;17(5):661-3
pubmed: 24728269
Hum Mol Genet. 2003 Oct 15;12(20):2587-97
pubmed: 12925569
J Neurochem. 2000 Sep;75(3):991-1003
pubmed: 10936180
J Biol Chem. 2011 Jan 7;286(1):35-41
pubmed: 21051542
Psychopharmacology (Berl). 2012 Aug;222(4):709-19
pubmed: 22451092
Neurology. 2019 Apr 30;92(18):829-830
pubmed: 30952790
Nat Commun. 2018 Oct 12;9(1):4230
pubmed: 30315172
PLoS One. 2008 Jul 23;3(7):e2750
pubmed: 18648646
Neurobiol Aging. 2011 Dec;32(12):2321.e1-12
pubmed: 20579773
Alzheimers Res Ther. 2017 Apr 27;9(1):29
pubmed: 28446202
Nat Biotechnol. 2020 Sep;38(9):1087-1096
pubmed: 32440005
Drug Discov Today. 2013 Apr;18(7-8):350-7
pubmed: 22897878
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Genome Res. 2011 Mar;21(3):364-76
pubmed: 21163940
Nat Commun. 2020 Jan 30;11(1):619
pubmed: 32001681
Neuron. 2010 Jun 10;66(5):631-45
pubmed: 20547123
Front Neurosci. 2020 Dec 04;14:614643
pubmed: 33343293
Nat Rev Immunol. 2013 Jan;13(1):46-57
pubmed: 23237964
Cardiovasc Res. 2009 Oct 1;84(1):64-71
pubmed: 19477965
Neuron. 2003 Jul 31;39(3):409-21
pubmed: 12895417
Cell Rep. 2017 Nov 21;21(8):2304-2312
pubmed: 29166618
Aging Cell. 2013 Dec;12(6):1082-90
pubmed: 23862663
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526